General Information of Drug (ID: DMCMD93)

Drug Name
SSR149415 Drug Info
Synonyms
Nelivaptan; SSR 149415; 439687-69-1; UNII-3TY57MQ4OA; SR-149415; SSR-149415; 3TY57MQ4OA; CHEMBL582857; Nelivaptan [INN]; DSSTox_CID_27358; DSSTox_RID_82294; DSSTox_GSID_47358; GTPL2202; DTXSID7047358; SCHEMBL14517029; MolPort-042-665-640; Tox21_300240; BDBM50299343; ZINC42833251; DB12643; SSR-149,415; NCGC00254222-01; NCGC00247960-01; CAS-439687-69-1; (2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxoindol-3-yl]-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide; Nelivaptan; 1-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide
Indication
Disease Entry ICD 11 Status REF
Anxiety disorder 6B00-6B0Z Phase 2 [1]
Major depressive disorder 6A70.3 Phase 2 [1]
Cross-matching ID
PubChem CID
9895468
CAS Number
CAS 439687-69-1
TTD Drug ID
DMCMD93

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Desmopressin DMS3GVE Diabetic complication 5A2Y Approved [5]
Mozavaptan DMZ905C Hyponatraemia 5C72 Approved [6]
Oxytocin DMDL27I Autism spectrum disorder 6A02 Approved [7]
ATOSIBAN DMB7WYM N. A. N. A. Phase 4 [8]
ABT-436 DMNAU1V Anxiety disorder 6B00-6B0Z Phase 2 [9]
ARGENINE VASOPRESSIN DM8KN0Q Discovery agent N.A. Investigative [10]
D[Arg4,Orn8]VP DM8D4QT Discovery agent N.A. Investigative [10]
D[Leu4,Lys8]VP DMDBU7Q Discovery agent N.A. Investigative [10]
D[Arg4,Lys8]VP DM69OVM Discovery agent N.A. Investigative [10]
D[Cha4,Lys8]VP DM0GO7U Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Desmopressin DMS3GVE Diabetic complication 5A2Y Approved [5]
Mozavaptan DMZ905C Hyponatraemia 5C72 Approved [11]
Oxytocin DMDL27I Autism spectrum disorder 6A02 Approved [12]
Tolvaptan DMIWFRL Autosomal dominant polycystic kidney disease GB81 Approved [13]
Conivaptan DM1V329 Euvolemic hyponatremia 5C72 Approved [14]
Vasopressin DMQ2FPC Diabetes insipidus 5A61.5 Approved [15]
ATOSIBAN DMB7WYM N. A. N. A. Phase 4 [8]
Lixivaptan DMDN4ZP Hyponatraemia 5C72 Phase 3 [16]
Satavaptan DME5PN3 Acute and chronic heart failure BD1Z Phase 3 [17]
ASP-7035 DMTF24A Nocturia MF55 Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Desmopressin DMS3GVE Diabetic complication 5A2Y Approved [5]
Mozavaptan DMZ905C Hyponatraemia 5C72 Approved [19]
Oxytocin DMDL27I Autism spectrum disorder 6A02 Approved [20]
Conivaptan DM1V329 Euvolemic hyponatremia 5C72 Approved [14]
Felypressin DMHLP9C Localisation N.A. Approved [21]
Terlipressin DMT9FH3 Hypertension BA00-BA04 Approved [22]
ATOSIBAN DMB7WYM N. A. N. A. Phase 4 [8]
Balovaptan DMKMTDG Autism spectrum disorder 6A02 Phase 3 [23]
PMX-53 DMZUAJ4 Atopic dermatitis EA80 Phase 2 [24]
VA-111913 DMAYWXD Dysmenorrhea GA34.3 Phase 2 [25]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Oxytocin receptor (OTR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Desmopressin DMS3GVE Diabetic complication 5A2Y Approved [5]
Oxytocin DMDL27I Autism spectrum disorder 6A02 Approved [26]
Carbetocin DMUSLW3 Postpartum haemorrhage JA43 Approved [21]
ATOSIBAN DMB7WYM N. A. N. A. Phase 4 [27]
Retosiban DMOYGZF Preterm labour JB00 Phase 3 [28]
Barusiban DMWI0X3 Androgen deficiency 5A81.1 Phase 2 [29]
FE-202767 DMDGZ1C Erectile dysfunction HA01.1 Phase 2 [26]
GSK-557296 DM3ZL2O Premature ejaculation HA03.0Z Phase 2 [30]
Pyrrolidine derivative 13 DM3VA8P N. A. N. A. Patented [31]
PMID28906174-Compound-figure1g DMECU90 N. A. N. A. Patented [31]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ivacaftor DMZC1HS Cystic fibrosis CA25 Approved [32]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [33]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [34]
Quercetin DM3NC4M Obesity 5B81 Approved [35]
Miglustat DM5J64S Niemann-Pick disease type C Approved [36]
Glibenclamide DM8JXPZ Diabetic complication 5A2Y Approved [37]
Milrinone DM8TUPF Congestive heart failure BD10 Approved [34]
Oxidized glutathione DM9EQC0 Breast cancer 2C60-2C65 Approved [38]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [38]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [39]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oxytocin receptor (OTR) TTSCIUP OXYR_HUMAN Inhibitor [2]
Vasopressin V1a receptor (V1AR) TT4TFGN V1AR_HUMAN Inhibitor [2]
Vasopressin V1b receptor (V1BR) TTL9MHW V1BR_HUMAN Antagonist [3]
Vasopressin V2 receptor (V2R) TTK8R02 V2R_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Gene/Protein Processing [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2202).
2 Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
3 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
4 Vasotocin and vasopressin stimulation of the chloride secretion in the human bronchial epithelial cell line, 16HBE14o-. Br J Pharmacol. 2005 Apr;144(8):1037-50. doi: 10.1038/sj.bjp.0706103.
5 Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
6 New analgesic drugs derived from phencyclidine. J Med Chem. 1981 May;24(5):496-9.
7 The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
8 The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
9 The vasopressin Avprlb receptor: Molecular and pharmacological studies. Stress. 2011 January; 14(1): 98-115.
10 Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
11 Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
13 Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 May 1;419(3):577-84.
14 Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23.
15 Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9.
16 Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95.
17 Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J. 2009 Apr 15;419(2):507-17.
18 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030285)
19 Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65.
20 Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
21 Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
22 Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31.
23 Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder. J Med Chem. 2020 Feb 27;63(4):1511-1525.
24 Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
25 Clinical pipeline report, company report or official report of Avarx.
26 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
27 Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9.
28 The Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the Response of Human Myometrial Explants to Prolonged Mechanical Stretch.Endocrinology.2015 Oct;156(10):3511-6.
29 The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2009 Jun;200(6):627.e1-10.
30 Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. Br J Pharmacol. 2013 Aug;169(7):1477-85.
31 A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.
32 Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.
33 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
34 Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
35 Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol. 2004 Sep;31(3):351-7. doi: 10.1165/rcmb.2002-0086OC. Epub 2004 Jun 10.
36 Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622. J Pharmacol Exp Ther. 2008 Apr;325(1):89-99. doi: 10.1124/jpet.107.134502. Epub 2008 Jan 29.
37 Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J Membr Biol. 2003 Jul 15;194(2):109-17. doi: 10.1007/s00232-003-2030-z.
38 Reversible silencing of CFTR chloride channels by glutathionylation. J Gen Physiol. 2005 Feb;125(2):127-41. doi: 10.1085/jgp.200409115. Epub 2005 Jan 18.
39 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.